Active	Status	Sponsor type	Region	Phase	Filter
2 Active 5 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
JX11502MA / Zhejiang Jingxin Pharma
NCT06356389: A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.	Completed	1/2	60	RoW	JX11502MA, Placebo	Zhejiang Jingxin Pharmaceutical Co., Ltd., Shanghai Mental Health Center	Schizophrenia	12/22	01/23
NCT05233657: A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule	Recruiting	1	58	RoW	JX11502MA, Placebo	Zhejiang Jingxin Pharmaceutical Co., Ltd.	Schizophrenia	01/22	02/22

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
JX11502MA / Zhejiang Jingxin Pharma
NCT06356389: A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.	Completed	1/2	60	RoW	JX11502MA, Placebo	Zhejiang Jingxin Pharmaceutical Co., Ltd., Shanghai Mental Health Center	Schizophrenia	12/22	01/23
NCT05233657: A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule	Recruiting	1	58	RoW	JX11502MA, Placebo	Zhejiang Jingxin Pharmaceutical Co., Ltd.	Schizophrenia	01/22	02/22